The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Murkamilov I.T.

Akhunbaev Kyrgyz State Medical Academy, Bishkek, Kyrgyzstan;
Kyrgyz Russian Slavic University named after the First President of Russia B.N. Yeltsin, Bishkek, Kyrgyzstan

Sabirov I.S.

Kyrgyz- Russian Slavic University named after the First President of Russia B.N. Yeltsin, Bishkek, Kyrgyzstan

Fomin V.V.

I.M. Sechenov First State Moscow Medical University

Yusupov F.A.

Osh State University, Osh, Kyrgyzstan

Endothelial dysfunction and arterial wall stiffness: New targets in diabetic nephropathy

Authors:

Murkamilov I.T., Sabirov I.S., Fomin V.V., Yusupov F.A.

More about the authors

Journal: Therapeutic Archive. 2017;89(10): 87‑94

DOI: 10.17116/terarkh2017891087-94

Read: 2098 times

Download PDF (RU)
Contact the author
Table of contents

ENDOTHELIAL DYSFUNCTION AND ARTERIAL WALL STIFFNESS: NEW TARGETS IN DIABETIC NEPHROPATHY
ENDOTHELIAL DYSFUNCTION AND ARTERIAL WALL STIFFNESS: NEW TARGETS IN DIABETIC NEPHROPATHY

To cite this article:

Murkamilov IT, Sabirov IS, Fomin VV, Yusupov FA. Endothelial dysfunction and arterial wall stiffness: New targets in diabetic nephropathy. Therapeutic Archive. 2017;89(10):87‑94. (In Russ.)
https://doi.org/10.17116/terarkh2017891087-94

МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Reco­gnan (citicoline) prescribing in cere­brovascular diseases and type 2 diabetes mellitus patients. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(9):23-27
The role of biomarkers of endo­thelial dysfunction in predicting the progression of mild cognitive impairment in patients with cardiovascular risk factors. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(9):88-95
Morphofunctional and biochemical dete­rminants of endo­thelial function in patients with a new coro­navirus infe­ction COVID-19. Russian Journal of Preventive Medi­cine. 2024;(10):90-96
Changes in the lipid profile, stru­ctural and functional states of blood vessels in patients with lymphomas and cardiovascular toxic risks during the chemotherapy. Russian Journal of Preventive Medi­cine. 2024;(10):117-124
The significance of exogenous nitrate and nitrite of plant origin for vascular health. Russian Journal of Preventive Medi­cine. 2024;(11):141-146
Asse­ssment of risk of deve­loping fractures and sarcopenia and quality of life of patients with chro­nic kidney disease at the outpatient stage. Russian Journal of Preventive Medi­cine. 2024;(12):88-91
Features of arte­rial blood flow velo­city characteristics in endo­thelial dysfunction. Russian Journal of Preventive Medi­cine. 2024;(12):100-106
Long-term outcomes in patients after hospital treatment for COVID-19 (three-year follow-up data). Russian Journal of Preventive Medi­cine. 2024;(12):114-121
The role of quantitative body composition analysis in popu­lation in the asse­ssment and moni­toring of cardiovascular risk meta­bolic factors. Russian Journal of Preventive Medi­cine. 2024;(12):128-134
Asso­ciation of the subclinical athe­rosclerosis with addi­tional risk factors for chro­nic non-communicable diseases. Russian Journal of Preventive Medi­cine. 2024;(12):151-155
Abstract:

In recent years, one of the promising areas in clinical medicine is the study of impaired ments in endothelial function and arterial wall stiffness, which can be referred to as one of the important predictors of cardiovascular events in patients with chronic kidney disease, including that of diabetic etiology. There is strong evidence that endothelial function and great artery stiffness may be used as reliable clinical and instrumental indicators to evaluate the efficiency of therapeutic measures and the rate of progression of cardiovascular disorders in type 2 diabetes mellitus. The article presents data on the role of endothelial dysfunction and arterial wall stiffness in the progression of chronic kidney disease in type 2 diabetes mellitus and discusses the possibility of their correction with pharmacological agents.

Keywords:

chronic kidney disease
diabetes mellitus
cardiovascular diseases
endothelial dysfunction
arterial wall stiffness

Authors:

Murkamilov I.T.

Akhunbaev Kyrgyz State Medical Academy, Bishkek, Kyrgyzstan;
Kyrgyz Russian Slavic University named after the First President of Russia B.N. Yeltsin, Bishkek, Kyrgyzstan

Sabirov I.S.

Kyrgyz- Russian Slavic University named after the First President of Russia B.N. Yeltsin, Bishkek, Kyrgyzstan

Fomin V.V.

I.M. Sechenov First State Moscow Medical University

Yusupov F.A.

Osh State University, Osh, Kyrgyzstan

Close metadata

References:

  1. Mukhin NA, Fomin VV, Moiseev SV. et al. Sudden cardiac death in patients with chronic kidney disease. Clinical Nephrology. 2014;3;43-46. (In Russ.)
  2. Dedov II, Shestakova MV. Diabetes mellitus and Chronic kidney disease. Moscow: Medical news Agency; 2009. (In Russ.)
  3. The prevalence of type 2 diabetes mellitus in the adult population of Russia (NATION study). Dedov II, Shestakova MV, Galstyan GR. Diabetes Mellitus. 2016;19 (2):104-112. (In Russ.)
  4. Konyuh EA, Paramonov NS. Clinical features of acute and chronic glomerulonephritis in children with endothelial dysfunction. J Gr St Med University. 2010;2:149. (In Russ.)
  5. Kozlovskaya LV, Rameev VV, Bobkova IN et al. Role of endothelial dysfunction in progression of chronic glomerulonephritis, modern possibilities of its correction. Therapeutic archive. 2005;6:92-96. (In Russ.)
  6. Nephrology: guidelines for doctors. The editorship of SI Ryabov and IA Rakityansky Spetslit. 2013.767. (In Russ.)
  7. Pollak VE, Thornley-Brown D, Kant KS et al. A case study of a recent decline in the dialysis fatality rate. Contrib Nephrol. 1993;102:59-72. PMID:8416189
  8. Gerasimchuk PA, Kisil PV, Vlasenko VG et al. Indicators of endothelial dysfunction in patients with diabetic foot syndrome. Bulletin of the Russian Academy of medical Sciences. 2014;5-6:107-110. (In Russ.)
  9. Sokolova AV, Kochegura TN, Parfyonova EV et al. Examination number of circulating progenitor endothelial cells in patients with type 1 diabetes mellitus. Diabetes mellitus. 2015;18(3):51-56. (In Russ.)
  10. Shlipak MG, Fried LF, Crump C et al. Elevations of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency.Circulation. 2003;107(1):87-92. PMID:12515748
  11. Zuo Y, Yancey P, Castro I et al. Renal dysfunction potentiates foam cell formation by repressing ABCA1. Arterioscler Thromb Vasc Biol. 2009;29:9:1277-1282. https://doi.org/10.1161/ATVBAHA.109.188995
  12. Babushkina AV. Effectiveness of oral administration of L-arginine in patients with endothelial dysfunction. Ukrainian med journal. 2010;1:75:24-30. (In Russ.)
  13. Çakar M, Balta Ş, Şarlak H et al. Arterial stiffness and endothelial inflammation in prediabetes and newly diagnosed diabetes patients. Arch Endocrinol Metab. 2015;59(5):21.407-413. https://doi.org/10.1590/2359-3997000000061
  14. Brunner H, Cockcroft JR, Deanfield J et al. Working Group on Endothelins and Endothelial Factors of the European Society of Hypertension Endothelial function and dysfunction. Part II:Association with cardiovascular risk factors and diseases. A statement by the Working Group on Endothelins and Endothelial Factors of the European Society of Hypertension. J Hypertens. 2005;23(2):233-246. PMID:15662207
  15. Anavekar NS, Gans DJ, Berl T et al. Predictors of cardiovascular events in patients with type 2 diabetic nephropathy and hypertension:a case for albuminuria. Kidney Int Suppl. 2004;(92):S50-S55. https://doi.org/10.1111/j.1523-1755.2004.09213.x
  16. Arnlöv J, Evans JC, Meigs JB et al. Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals:the Framingham Heart Study. Circulation. 2005;112(7):969-975. https://doi.org/10.1161/CIRCULATIONAHA.105.538132
  17. Hillege H, Van Gilst W, de Zeeuw D et al. Renal function as a predictor of prognosis in chronic heart failure. Heart Fail Monit. 2002;2 (3):78-84. PMID:12634888
  18. Anavekar NS, Pfeffer MA. Cardiovascular risk in chronic kidney disease. Kidney Int Suppl. 2004;(92):S11-S15. https://doi.org/10.1111/j.1523-1755.2004.09203.x
  19. Navar LG, Harrison-Bernard LM, Imig JD et al. Intrarenal angiotensin II generation and renal effects of ATI receptor blockade. J Am Soc Nephrol. 1999;10:266-272. PMID:10201881.
  20. Klahr S. Progression of chronic renal disease. Heart Dis. 2001;3(3):205-209. PMID:11975793
  21. Melnikova YS, Makarova TP. Endothelial dysfunction as the key link of chronic diseases pathogenesis. Kazanskiy meditsinskiy zhurnal. 2015;96:4:659-665. (In Russ.)
  22. Heitzer T, Schlinzig T, Krohn K et al. Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation. 2001;104(22):2673-2678. Erratum in: Circulation. 2003;108(4):500. PMID:11723017.
  23. Perticone F., Ceravolo R., Pujia A. et al. Prognostic significance of endothelial dysfunction in hypertensive patients. Circulation. 2001;104(2):191-196. PMID:11447085
  24. Raptis AE, Viberti G. Pathogenesis of diabetic nephropathy. Exp Clin Endocrinol Diabetes. 2001;109(Suppl.2):S424-S437. https://doi.org/10.1055/s-2001-18600
  25. Annuk M., Zilmer M., Fellström B. Endothelium-dependent vasodilation and oxidative stress in chronic renal failure:impact on cardiovascular disease. Kidney Int Suppl. 2003;(84):S50-Ы53. https://doi.org/10.1046/j.1523-1755.63.s84.2.x
  26. Petrishchev NN. Dysfunction of the endothelium. The causes, mechanisms, pharmacological correction. S.-Petersburg. 2003;181. (In Russ.)
  27. Shchukin AA, Bobkova IN, Shestakova MV et al. Urinary excretion of markers of podocyte injury in patients with diabetes mellitus. Therapeutic archive. 2015;87(10):62-66. (In Russ.)
  28. Greive KA, Nikolic-Patzerson DJ, Guimaraes MA et al. Glomerular permselectivity factors are not responsible for the increase in fractional clearance of albumin in rat glomerulonephritis. Am J Pathol. 2001;159:1159-1170. https://doi.org/10.1016/S0002-9440(10)61792-0
  29. Vasilkova ON, Mokhort TV, Naumenko EP et al. Сlinical evaluation of risk factors for carotid atherosclerosis in patients with type 2 diabetes complicated with chronic kidney disease. Nephrology. 2016;1:20:62-68. (In Russ.)
  30. Nedogoda SV, Ilyukhin OV, Ivanenko VV. The Dynamics of indicators of elasticity of the vascular wall in patients with heart failure after acute myocardial infarction. Heart failure. 2009;4:2:95-98. (In Russ.)
  31. Kobalava ZD, Kotovskaya Yu, Barkov AB et al. High systolic blood pressure:the emphasis on the elastic properties of the arteries. Cardiovascular therapy and prophylactics. 2006;5:10-16. (In Russ.)
  32. Gardner JP, Li S, Srinivasan SR et al. Rise in insulin resistance is associated with escalated telomere attrition. Circulation. 2005; 111(17):2171-2177. https://doi.org/10.1161/01.CIR.0000163550.70487.0B
  33. Ilyukhin OV, Lopatin YuM. Velocity of the pulse wave and the elastic properties of arteries:factors that affect their mechanical properties, the possibility of diagnostic assessment. Volga Bulletin. 2006;17:3-8. (In Russ.)
  34. Glezer MG, Pul’sovoe AD: pochemu eto vazhno? M.: Medikom, 2013. (In Russ.)
  35. Bortolotto LA, Safar ME, Billaud E et al. Plasma homocysteine, aortic stiffness, and renal function in hypertensive patients. Hypertension. 1999;34:837-42. PMID:10523370
  36. Booth AD, Wallace S, McEniery CM et al. Inflammation and arterial stiffness in systematic vasculites:a model of vascular inflammation. Arthritis Rheum. 2004;50:581-857. https://doi.org/10.1002/art.20002
  37. Hirai T, Sasayama S, Kawasaki T et al. Stiffness of systemic arteries in patients with myocardial infarction. A noninvasive method to predict severity of coronary atherosclerosis. Circulation. 1989;80:78-86. PMID:2610739
  38. van Popele NM, Grobbee DE, Bots ML et al. Association Between Arterial Stiffness and Atherosclerosis. Stroke. 2001;32:454-460. PMID:11157182
  39. Kimoto E., Shoji T., Shinohara K. et al. Regional Arterial Stiffness in Patients with Type 2 Diabetes and Chronic Kidney Disease. J Am Soc Nephrol. 2006;17:2245-2252. https://doi.org/10.1681/ASN.2005101038
  40. László A., Reusz G., Nemcsik J. Ambulatory arterial stiffness in chronic kidney disease:a methodological review. Hypertension Research. 2016;39:192-198. https://doi.org/10.1038/hr.2015.137
  41. Elewa U, Fernandez-Fernandez B, Alegre R et al. Modifiable Risk Factors for Increased Arterial Stiffness in Outpatient Nephrology. PloS one. 2015;10:4:e0123903. April 16, 2015. https://doi.org/10.1371/journal.pone.0123903
  42. Kravtsova OA, Pavlova EA, Kotovskaya YuV et al. Feature of renin profile and parameters of arterial stiffness in patients with previously untreated arterial hypertension. Rational pharmacotherapy in cardiology. 2014;1:31-36. (In Russ.)
  43. Benetos A, Adamopoulos C, Bureau JM et al. Determinants of progression of arterial stiffness in normotensive subjects and treated hypertensive subject over a 6-year period. Circulation. 2002;105:1202-1207. PMID:11889014
  44. Kuo TH, Yang DC, Lin WH et al. Compliance Index, a Marker of Peripheral Arterial Stiffness, may Predict Renal Function Decline in Patients with Chronic Kidney Disease. Int J Med Sci. 2015;12(7):530-537. https://doi.org/10.7150/ijms.12164
  45. Adel M, ELSheikh A, Sameer S. Arterial stiffness in metabolic syndrome. J Saudi Heart Assoc. 2016;1:5:1-8. https://doi.org/10.1016/j.jsha.2015.12.005
  46. Vuurmans T, Boer P, Koomans H. Effects of endothelin-1 and endothelin-1 receptor blockade on cardiac output, aortic pressure, and pulse wave velocity in humans. Hypertension. 2003;41:1253-1258. https://doi.org/10.1161/01.HYP.0000072982.70666.E8
  47. Guseva MV, Zakharova N, Kurmaev DP. Characterization of the stiffness of arteries in patients of senile age with chronic kidney disease in combination with ischemic heart disease and hypertension. Successes of gerontology. 2013;2:320-325. (In Russ.)
  48. Statsenko ME, Derevyanchenko MV, Titarenko MN et al. Cardiorenal relationships in hypertensive patients with type 2 diabetes. Nephrology. 2014;5:18:51-58. (In Russ.)
  49. Belenkov YuN, Privalova EV, Danilovicha YuA et al. Effect of 12-month therapy with perindopril Aon structural and functional state of the microvasculature in patients with chronic heart failure. Cardiology. 2015.12.5-10. (In Russ.)
  50. Kobalava JD, Kotovsky JV, Bogomaz AV. Fixed combination of bisoprolol and amlodipine eliminates the impact of β-blocker on the parameters of Central pulse wave in patients with arterial hypertension. Cardiology. 2015;12:11 try out-16. (In Russ.)
  51. Sizova ZhM, Kozlova NIn, Zakharova VL et al. Comparative evaluation of the effect of isosorbidedinitrate, isosorbide-5-Mononitrate and nicorandil on the frequency of angina attacks and vessel regulation function of endothelium in patients with coronary heart disease. Cardiology. 2015;2:10-15. (In Russ.)
  52. Ullian M, Schelling J, Linas S. Aldosterone enhances angiotensin II receptor binding and inositol phosphate responses. Hypertension. 1992;20:67-73. PMID:1618554.
  53. Greene E, Kren S, Hostetter T. Role of aldosterone in the remnant kidney model in the rat. J Clin Invest. 1996;98:1063-1068. https://doi.org/10.1172/JCI118867
  54. Edwards NC, Ferro CJ, Kirkwood H et al. Effect of spironolactone on left ventricular systolic and diastolic function in patients with early stage chronic kidney disease. Am J Cardiol. 2010;106(10):1505-1511. https://doi.org/10.1016/j.amjcard.2010.07.018
  55. Kayukov IG, Yesayan AM, Karabaeva AZ. Characteristics of left ventricle remodeling in patients with chronic kidney disease and the influence of the therapy with spironolactone. Clinical medicine. 2007;12:44-48. (In Russ.)
  56. Matsumoto Y, Mori Y, Kageyama S et al. Spironolactone reduces cardiovascular and cerebrovascular morbidity and mortality in hemodialysis patients. J Am Coll Cardiol. 2014;63:528-536. https://doi.org/10.1016/j.jacc.2013.09.056
  57. Ichihara A, Kaneshiro Y, Takemitsu T et al. The (pro) renin receptor and the kidney. Semin Nephrol. 2007;27(5):524-528. https://doi.org/10.1016/j.semnephrol.2007.07.00
  58. Bobkova IN, Shestakova MV, Shchukina AA. Podocyte injury in diabetes mellitus. Diabetes mellitus. 2014;(3):39-50. (In Russ.)
  59. Dhaun N, Moorhouse R, MacIntyre IM et al. Diurnal variation in blood pressure and arterial stiffness in chronic kidney disease:the role of endothelin-1. Hypertension. 2014;64(2):296-304. https://doi.org/10.1161/HYPERTENSIONAHA.114.03533
  60. Kuznetsov IS, Serezhenkov VA, Romantsova TI et al. Metformin regulates glycemic homeostasis in patients with type 2 diabetes mellitus as an NO donor. Diabetes mellitus. 2013;(3):41-45. (In Russ.)
  61. Surkova EV, Mel’nikova OG. Some aspects of drug therapy adherence in patients with diabetes mellitus type 2. Difficult patient. 2008;11:6:35-38. (In Russ.)
  62. Kagramanyan IN, Malygin AYu, Khokhlov AL et al. Aspects of correction of endothelial dysfunction in ischemic stroke. Archives of internal medicine. 2013;4;12;24-29. (In Russ.)
  63. Uеhara G, Takeda H. Relative effects of telmisartan, candesartan and losartan on alleviating arterialstiffness in patients with hypertension complicated by diabetes mellitus:an evaluation using the cardio-ankle vascular index (CAVI). J Intern Med Res. 2008;36: 1094-102. PMID:18831906
  64. Sasamura H, Kitamura Y, Nakamura M et al. Effects of angiotensin receptor blocker candesartan on arterial stiffness and markers of extracellular matrix metabolism in patients with essential hypertension. Сlin Experim Hypertens. 2006;28:511-520. https://doi.org/10.1080/10641960600798721
  65. Frimodt-Moller M., Kamper A.L., Strandgaard S. et al. Beneficial effects on arterial stiffness and pulse-wave reflection of combined enalapril and candesartan in chronic kidney disease — a randomized trial. PLoS One. 2012;7(7):e41757. https://doi.org/10.1371/journal.pone.0041757
  66. Malacco E, Omboni S, Parati G. Blood Pressure Response to Zofenopril or Irbesartan Each Combined with Hydrochlorothiazide in High-Risk Hypertensives Uncontrolled by Monotherapy:A Randomized, Double-Blind, Controlled, Parallel Group, Noninferiority Trial. Int J Hypertens. 2015;2015:139465. https://doi.org/10.1155/2015/139465
  67. Pasini AF, Garbin U, Nava MC et al. Effect of sulfhydryl and nonsulfhydryl angiotensin-converting enzyme inhibitors on endothelial function in essential hypertensive patients. Am J Hypertens. 2007;20(4):443-450. PMID:17386354
  68. Napoli C, Sica V, de Nigris F et al. Sulfhydryl angiotensin-converting enzyme inhibition induces sustained reduction of systemic oxidative stress and improves the nitric oxide pathway in patients with essential hypertension. Am Heart J. 2004;7:148(1):e5. https://doi.org/10.1016/j.ahj.2004.03.025
  69. Borovkova NYu, Kuznetsova TE, Borovkov NN et al. Treatment of hypertension in patients with chronic heart failure with signs of chronic kidney disease combined preparation of perindopril arginine and amlodipine. Cardiology. 2015;6:22-26. (In Russ.)
  70. Prokofyeva EB, Glezer MG. Arterial wall stiffness and central hemodynamic parameters on the background of long-term combined antihypertensive therapy. Cardiology. 2015.4.19-24. (In Russ.)
  71. Oleynikov VE, Matrosova IB, Melnikova EA. Favorable effect of olmesartan on the performance of local rigidity using the technology of the echo-tracking. Cardiology. 2014;9:39-45. (In Russ.)
  72. Omboni S, Posokhov IN, Parati G et al. Vascular Health Assessment of The Hypertensive Patients (VASOTENS) Registry:Study Protocol of an International, Web-Based Telemonitoring Registry for Ambulatory Blood Pressure and Arterial Stiffness. JMIR Res Protoc. 2016;29;5(2):e137. https://doi.org/10.2196/resprot.5619
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.